A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
- Conditions
- Interventions
- First Posted Date
- 2019-12-16
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 33
- Registration Number
- NCT04200456
- Locations
- 🇺🇦
Tp0003 20062, Ivano-frankivsk, Ukraine
🇺🇦Tp0003 20100, Zaporizhzhia, Ukraine
🇲🇩Tp0003 20051, Chisinau, Moldova, Republic of
A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP)
- First Posted Date
- 2019-12-04
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 25
- Registration Number
- NCT04185415
- Locations
- 🇬🇧
Psp003 40166, London, United Kingdom
🇩🇪Psp003 40278, Essen, Germany
🇪🇸Psp003 40267, Barcelona, Spain
A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)
- Conditions
- Interventions
- First Posted Date
- 2019-11-14
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 22
- Registration Number
- NCT04163016
- Locations
- 🇨🇭
Up0085 300, Bern, Switzerland
🇫🇷Up0085 500, Paris, France
🇺🇸Up0085 104, Minneapolis, Minnesota, United States
A Study to Test the Interaction of Padsevonil With Oral Contraceptives in Healthy Female Participants
- Conditions
- Interventions
- First Posted Date
- 2019-10-18
- Last Posted Date
- 2021-06-24
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 14
- Registration Number
- NCT04131517
- Locations
- 🇬🇧
Up0035 001, London, United Kingdom
A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
- First Posted Date
- 2019-10-14
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 71
- Registration Number
- NCT04124965
- Locations
- 🇺🇸
Mg0004 50088, Washington, District of Columbia, United States
🇨🇦Mg0004 50070, Québec, Canada
🇺🇸Mg0004 50096, Philadelphia, Pennsylvania, United States
A Study to Evaluate the Efficacy, Safety, and Drug Concentration of Certolizumab Pegol (CZP) in Children and Adolescent Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO)
- Conditions
- Interventions
- First Posted Date
- 2019-10-11
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 150
- Registration Number
- NCT04123795
- Locations
- 🇺🇸
Ps0007 50214, Auburn, Alabama, United States
🇺🇸Ps0007 50175, Phoenix, Arizona, United States
🇺🇸Ps0007 50213, Anaheim, California, United States
A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis
- First Posted Date
- 2019-10-01
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 214
- Registration Number
- NCT04109976
- Locations
- 🇵🇱
Dv0004 40097, Warsaw, Poland
🇺🇸Dv0004 50125, Charlotte, North Carolina, United States
🇺🇸Dv0004 50024, Boise, Idaho, United States
A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice
- First Posted Date
- 2019-08-13
- Last Posted Date
- 2023-01-23
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 412
- Registration Number
- NCT04053881
- Locations
- 🇩🇪
Ps0026 529, Gladbeck, Germany
🇩🇪Ps0026 518, Karlsruhe, Germany
🇩🇪Ps0026 532, Bogen, Germany
A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Conditions
- Interventions
- First Posted Date
- 2019-08-09
- Last Posted Date
- 2022-11-03
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 21
- Registration Number
- NCT04051944
- Locations
- 🇺🇸
Cidp04 50080, Durham, North Carolina, United States
🇺🇸Cidp04 50075, Augusta, Georgia, United States
🇬🇧Cidp04 40167, Sheffield, United Kingdom
A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 1131
- Registration Number
- NCT04009499
- Locations
- 🇺🇸
Pa0012 50028, Lexington, Kentucky, United States
🇷🇺Pa0012 20012, Ryazan, Russian Federation
🇺🇸Pa0012 50005, Freehold, New Jersey, United States